Formyl peptide receptors (FPRs) are G-protein-coupled receptors that play an important role in the regulation of inflammatory process and cellular dysfunction. In humans, three different isoforms are expressed (FPR1, FPR2, and FPR3). FPR2 appears to be directly involved in the resolution of inflammation, an active process carried out by specific pro-resolving mediators that modulate specific receptors. Previously, we identified 2-arylacetamido pyridazin-3(2H)-ones as FPR1- or FPR2-selective agonists, as well as a large number of mixed-agonists for the three isoforms. Here, we report a new series of 2-arylacetamido pyridazinones substituted at position 5 and their development as FPR agonists. We also synthesized a new series of 2-oxothiazolones bearing a 4-bromophenylacetamido fragment, which was fundamental for activity in the pyridazinone series. The compounds of most interest were 4a, a potent, mixed FPR agonist recognized by all three isotypes (FPR1 EC50519 nM, FPR2 EC50543 nM, FPR3 EC50540 nM), and 4b, which had potent activity and a preference for FPR2 (EC50513 nM). These novel compounds may represent valuable tools for studying FPR activation and signaling.

Synthesis of five and six-membered N-phenylacetamido substituted heterocycles as formyl peptide receptor agonists / Vergelli, Claudia; Schepetkin, Igor A.; Ciciani, Giovanna; Cilibrizzi, Agostino; Crocetti, Letizia; Giovannoni, Maria Paola; Guerrini, Gabriella; Iacovone, Antonella; Kirpotina, Liliya N.; Ye, Richard D.; Quinn, Mark T.. - In: DRUG DEVELOPMENT RESEARCH. - ISSN 1098-2299. - ELETTRONICO. - 78:(2017), pp. 49-62. [10.1002/ddr.21370]

Synthesis of five and six-membered N-phenylacetamido substituted heterocycles as formyl peptide receptor agonists

VERGELLI, CLAUDIA;CICIANI, GIOVANNA;CROCETTI, LETIZIA;GIOVANNONI, MARIA PAOLA;GUERRINI, GABRIELLA;IACOVONE, ANTONELLA;
2017

Abstract

Formyl peptide receptors (FPRs) are G-protein-coupled receptors that play an important role in the regulation of inflammatory process and cellular dysfunction. In humans, three different isoforms are expressed (FPR1, FPR2, and FPR3). FPR2 appears to be directly involved in the resolution of inflammation, an active process carried out by specific pro-resolving mediators that modulate specific receptors. Previously, we identified 2-arylacetamido pyridazin-3(2H)-ones as FPR1- or FPR2-selective agonists, as well as a large number of mixed-agonists for the three isoforms. Here, we report a new series of 2-arylacetamido pyridazinones substituted at position 5 and their development as FPR agonists. We also synthesized a new series of 2-oxothiazolones bearing a 4-bromophenylacetamido fragment, which was fundamental for activity in the pyridazinone series. The compounds of most interest were 4a, a potent, mixed FPR agonist recognized by all three isotypes (FPR1 EC50519 nM, FPR2 EC50543 nM, FPR3 EC50540 nM), and 4b, which had potent activity and a preference for FPR2 (EC50513 nM). These novel compounds may represent valuable tools for studying FPR activation and signaling.
2017
78
49
62
Goal 3: Good health and well-being for people
Vergelli, Claudia; Schepetkin, Igor A.; Ciciani, Giovanna; Cilibrizzi, Agostino; Crocetti, Letizia; Giovannoni, Maria Paola; Guerrini, Gabriella; Iaco...espandi
File in questo prodotto:
File Dimensione Formato  
ddr.Vergelli 2017.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 545.15 kB
Formato Adobe PDF
545.15 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1080980
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact